OPRX

AI Memo

OptimizeRx

As of 2026-09-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Finance leadership transition and deleveraging execution • 2027-01-01

Base target: $9 / p=50% prob

Biggest risk

Revenue declined 30% year over year, net revenue retention fell to 90% from 121%, and management cited customer-specific weakness plus second-half timing and mix variability. Low coverage leaves analyst revisions and estimate changes unavailable.

Invalidation

Break below $6 or thesis failure.

What would change my mind?

The Q2 adjusted EBITDA beat, reaffirmed full-year guidance, improved cash position, debt refinancing, principal paydown, and new platform capabilities support a cautiously constructive view.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-02

Base target

p=50%

Bull target

$12

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-Q2 earnings digestion
Platform commercialization and programmatic expansion
The Q2 adjusted EBITDA beat, reaffirmed full-year guidance, improved cash position, debt refinancing, principal paydown, and new platform capabilities support a cautiously constructive view.

BearKey bullets

Customer concentration and the loss or inactivity of large customers could pressure results.
Finance leadership transition could create execution or reporting risk.
Low analyst coverage means revisions, consensus breadth, and target changes are unavailable.

WatchKey bullets

Finance leadership transition and deleveraging execution

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $9 (p=50%)

Target spread vs base: +31% / -34%

Scenario probabilities

Bull Target: $12 (p=25%)Base Target: $9 (p=50%)Bear Target: $6 (p=25%)

Commentary

Primary-source evidence supports a cautiously constructive post-earnings view: profitability exceeded expectations and guidance held, but revenue contraction, weaker retention, sparse coverage, unavailable revisions, and absent social/options data limit confidence. Market reaction should be monitored for whether the earnings beat or demand concerns dominate.

As of 2026-09-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

The Q2 adjusted EBITDA beat, reaffirmed full-year guidance, improved cash position, debt refinancing, principal paydown, and new platform capabilities support a cautiously constructive view.

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-Q2 earnings digestion
Platform commercialization and programmatic expansion

Scenarios

Bull Target (Scenario probability)

$12 / p=25% prob

Base Target (Scenario probability)

$9 / p=50% prob

Bear Target (Scenario probability)

$6 / p=25% prob

Analysis 2026-09-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.55

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-01-01
Finance leadership transition and deleveraging execution
Edward Stelmakh is scheduled to step down as Chief Financial & Strategy Officer on December 31, 2026, with Andrew D’Silva becoming CFO on January 1, 2027. The company also reported term-loan paydown and completed refinancing [#SEC-8K-2026-08-12].
Prob 60.00% • Move 7.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Post-Q2 earnings digestion
2026-12-01
Q2 revenue was $20.5 million and adjusted EBITDA was $4.9 million, both above consensus; FY2026 revenue and adjusted EBITDA guidance was reaffirmed at $95-$100 million and $21-$25 million. Offsetting concerns include 30% year-over-year revenue contraction and 90% net revenue retention [#SEC-8K-2026-08-12] [#PR-EARNINGS-2026-08-19].
Prob 65% • Move 8% • Priced-in 75%

Long-term Catalysts

Months to a year

Platform commercialization and programmatic expansion
2027-09-02
DeepIntent integration with OptimizeRx’s authenticated EHR network, Natural Language Audience Builder, and CopayCue could support recurring growth and customer engagement, but revenue contribution and timing remain unquantified [#SEC-8K-2026-08-12].
Prob 45% • Move 20% • Priced-in 30%

Risks

Customer concentration and the loss or inactivity of large customers could pressure results.
Finance leadership transition could create execution or reporting risk.
Low analyst coverage means revisions, consensus breadth, and target changes are unavailable.
Platform initiatives have unquantified commercialization timing and financial contribution.
Revenue contraction and weaker net revenue retention may persist.
Second-half revenue timing and mix remain variable.

Peers

Symbol	Summary
INGN	Small-cap same-sector candidate with closer market-cap context; direct operating comparability to OptimizeRx is unverified.
KRMD	Small-cap same-sector candidate; useful for size context, but business-model comparability is unverified.
FOCL	Small-cap same-sector candidate; direct peer fit is unverified.
ABT	Large-cap medtech reference peer for sector context only; not a validated direct comparable.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-02

Loading AI feed…

Symbol

Summary

INGN

Small-cap same-sector candidate with closer market-cap context; direct operating comparability to OptimizeRx is unverified.

KRMD

Small-cap same-sector candidate; useful for size context, but business-model comparability is unverified.

FOCL

Small-cap same-sector candidate; direct peer fit is unverified.

ABT

Large-cap medtech reference peer for sector context only; not a validated direct comparable.